JUNS · Insider Trading
Jupiter Neurosciences, Inc. Common Stock
Every open-market purchase and sale reported by JUNS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Andrew Jon Cutler | Director | A | +472,222 deriv. | — |
| 2026-07-13 | Nicholas H. Hemmerly | Director | M | +95,550 | — |
| 2026-07-13 | Holger Weis | Director | M | +85,800 | — |
| 2026-07-13 | Marshall A. Hayward | Chief Scientific Officer | M | +1,014,195 | — |
| 2026-07-13 | Alexander Gustaf Erik Rosen | Chief Administrative Officer | M | +261,161 | — |
| 2026-07-13 | Julie B. Kampf | Director | M | +82,875 | — |
| 2026-07-01 | Tomas Jan Philipson | Director | A | +536,428 deriv. | — |
| 2026-06-05 | Allison W Brady | Director | A | +100,000 deriv. | — |
| 2026-06-04 | Christer Rosen | CEO and Chairman | A | +747,783 deriv. | — |
| 2026-06-04 | Marshall A. Hayward | Chief Scientific Officer | A | +259,231 deriv. | — |
| 2026-06-04 | Alison D. Silva | President and COO | A | +1,027,304 deriv. | — |
| 2026-06-04 | Julie B. Kampf | Director | A | +100,000 deriv. | — |
| 2026-06-04 | Saleem Elmasri | Chief Financial Officer | A | +525,565 deriv. | — |
| 2026-06-04 | Holger Weis | Director | A | +100,000 deriv. | — |
| 2026-06-04 | Nicholas H. Hemmerly | Director | A | +100,000 deriv. | — |
| 2026-06-04 | Alexander Gustaf Erik Rosen | Chief Administrative Officer | A | +341,843 deriv. | — |
| 2025-07-07 | Alison D. Silva | Pres + Chief Business Officer | A | +255,320 deriv. | — |
| 2025-07-07 | Saleem Elmasri | CFO and Secretary | M | +66,293 | — |
| 2025-07-03 | Christer Rosen | CEO and Chairman | Buy | +3,600 | +$3.67K |
| 2025-07-03 | Alison D. Silva | Pres + Chief Business Officer | Buy | +750 | +$772 |
| 2025-07-01 | Alison D. Silva | Pres + Chief Business Officer | MIXED | +112,027 | +$1.86K |
| 2025-07-01 | Christer Rosen | CEO and Chairman | MIXED | +981,282 | +$7.99K |
| 2025-01-24 | Allison W Brady | Director | M | +21,750 | — |
| 2025-01-24 | Holger Weis | Director | M | +10,781 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Christer Rosen | CEO and Chairman | 147,677 | $422.36K |
| Marshall A. Hayward | Chief Scientific Officer | 36,934 | $105.63K |
| Alexander Gustaf Erik Rosen | Chief Administrative Officer | 8,232 | $23.54K |
| Alison D. Silva | President and COO | 1,497 | $4.28K |
| Holger Weis | Director | 1,288 | $3.68K |
| Nicholas H. Hemmerly | Director | 1,274 | $3.64K |
| Julie B. Kampf | Director | 1,105 | $3.16K |
| Saleem Elmasri | Chief Financial Officer | 883 | $2.53K |
| Allison W Brady | Director | 290 | $829 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JUNS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.